肝癌试验发现,与单独服用TACE相比,布罗利祖马布和联瓦替尼的治疗没有提高存活率,但改善了无进展的存活率和严重副作用的增加. A liver cancer trial found pembrolizumab and lenvatinib with TACE didn’t boost survival vs. TACE alone but improved progression-free survival and increased severe side effects.

对未经治疗的、无法解剖的肝癌在TACE中添加了第3阶段试验测试pembromizumab和lenvatinib,但与仅TACE相比,这一阶段的总体存活率没有提高,导致早期试验结束。 A phase 3 trial testing pembrolizumab and lenvatinib added to TACE for untreated, unresectable liver cancer did not improve overall survival compared to TACE alone, leading to early trial closure. 然而,这种结合大大改善了无进步生存,中位数为14.6个月,而中位数为10.0个月,两年总存活率为75%,而总存活率则为69%。 However, the combination significantly improved progression-free survival, with a median of 14.6 months versus 10.0 months, and a 2-year overall survival rate of 75% versus 69%. 合并组群出现严重副作用的比率较高,包括4起与治疗有关的死亡。 Higher rates of severe side effects occurred in the combination group, including four treatment-related deaths. 结果发表在"柳叶刀"杂志上,证实了在ESMO 2024上提出的先前发现. Results were published in The Lancet and confirm prior findings presented at ESMO 2024.